We are already making an impact in several key areas that transform the drug discovery sector, such as the development of high-tech lab-based models of disease, advanced clinical imaging techniques, and targeting hard-to-treat diseases like antimicrobial resistance, cystic fibrosis and diseases associated with ageing.
We have helped companies advance their drugs into patient trials and their technology products on the market. Our R&D partners have raised over £1.9bn in private investment.
Focusing on the hard-to-do will enable innovators to de-risk their products and services, making them and the country successful and improving patient outcomes.
